Dupilumab in Adults and Adolescents with Eosinophilic EsophagitisEvan S. Dellon, Arsalan Shabbir, Marc E. Rothenberg et al.|New England Journal of Medicine|2022Cited by 452
A Phase <scp>II</scp> Trial of Lutikizumab, an Anti–Interleukin‐1α/β Dual Variable Domain Immunoglobulin, in Knee Osteoarthritis Patients With SynovitisRoy Fleischmann, Marc C. Levesque, Philip G. Conaghan et al.|Arthritis & Rheumatology|2019Cited by 209
Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of AgeMirna Chehade, Jennifer Maloney, Evan S. Dellon et al.|New England Journal of Medicine|2024Cited by 107
Dupilumab Improves Histologic And Endoscopic Outcomes In Children Aged 1 To <12 Years With Eosinophilic Esophagitis (EoE): 52-Week Results From The Phase 3 EoE KIDS TrialMirna Chehade, Arsalan Shabbir, Evan S. Dellon et al.|Journal of Allergy and Clinical Immunology|2024Cited by 7